<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">90027</article-id>
<article-id pub-id-type="doi">10.7554/eLife.90027</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.90027.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.3</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Computational and Systems Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3351-9514</contrib-id>
<name>
<surname>Heitmann</surname>
<given-names>Stewart</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">✉</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3859-3716</contrib-id>
<name>
<surname>Vandenberg</surname>
<given-names>Jamie I</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6403-1282</contrib-id>
<name>
<surname>Hill</surname>
<given-names>Adam P</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Victor Chang Cardiac Research Institute</institution>, Darlinghurst, NSW 2010, <country>Australia</country></aff>
<aff id="a2"><label>2</label><institution>School of Clinical Medicine, Faculty of Medicine and Health</institution>, UNSW Sydney, <country>Australia</country></aff>
<aff id="a3"><label>3</label><institution>Victor Chang Cardiac Research Institute Innovation Centre</institution>, Darlinghurst, NSW 2010, <country>Australia</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Huang</surname>
<given-names>Christopher L-H</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>University of Cambridge</institution>
</institution-wrap>
<city>Cambridge</city>
<country>United Kingdom</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ajijola</surname>
<given-names>Olujimi A</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of California, Los Angeles</institution>
</institution-wrap>
<city>Los Angeles</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>✉</label>Correspondence: <email>s.heitmann@victorchang.edu.au</email></corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-08-21">
<day>21</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP90027</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-06-22">
<day>22</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-06-07">
<day>07</day>
<month>06</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.19.537441"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Heitmann et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Heitmann et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-90027-v1.pdf"/>
<abstract>
<p>Many classes of drugs can induce fatal cardiac arrhythmias by disrupting the electrophysiology of cardiomyocytes. Safety guidelines thus require all new drugs to be assessed for pro-arrhythmic risk prior to conducting human trials. The standard safety protocols primarily focus on drug blockade of the delayed-rectifier potassium current (IKr). Yet the risk is better assessed using four key ion currents (IKr, ICaL, INaL, IKs). We simulated 100,000 phenotypically diverse cardiomyocytes to identify the underlying relationship between the blockade of those currents and the emergence of ectopic beats in the action potential. We call that relationship the axis of arrhythmia. It serves as a yardstick for quantifying the arrhythmogenic risk of any drug from its profile of multi-channel block alone. We tested it on 109 drugs and found that it predicted the clinical risk labels to an accuracy of 88.1% to 90.8%. Pharmacologists can use our method to assess the safety of novel drugs without resort to animal testing nor unwieldy computer simulations.</p></abstract>
<abstract abstract-type="teaser">
<title>Significance Statement</title>
<p>Many classes of drugs interfere with the electrical signaling of the heart, leading to arrhythmias and cardiac arrest. Newly developed drugs must therefore undergo mandatory safety testing in animals prior to human trials. Computational models of cardiac electrophysiology offer an ethical alternative but the current methods are difficult to apply beyond specialist computing laboratories. This study uses such models to identify the underlying relationship between drugs and cardiac arrhythmias. Those findings are then translated into a compact metric that can be applied using simple pen and paper calculations. The new metric allows pharmacology laboratories to assess the safety of novel drugs without using animals nor unwieldy computer simulations.</p></abstract>
<kwd-group kwd-group-type="author">
<kwd>cardiotoxicity</kwd>
<kwd>arrhythmia</kwd>
<kwd>safety pharmacology</kwd>
<kwd>electrophysiology</kwd>
</kwd-group>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Supplementary Dataset S1 was reformatted as comma separated values (CSV). The description of the dataset was revised. The description of the decision boundary was revised to emphasize that the analysis is conducted in four dimensions.</p></fn>
</fn-group>
<fn-group content-type="external-links">
<fn fn-type="dataset"><p>
<ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/7796721">https://zenodo.org/record/7796721</ext-link>
</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Torsades des Pointes is a potentially lethal ventricular arrhythmia that can be induced by many classes of drugs. These include antibiotics, antipsychotics, antihistamines, chemotherapeutics and antiarrhythmics (<xref ref-type="bibr" rid="c41">Yap and Camm, 2003</xref>). The majority of torsadogenic drugs block the hERG ion channel which carries the delayedrectifier potassium current (<italic>I</italic><sub>Kr</sub>) (<xref ref-type="bibr" rid="c39">Witchel, 2011</xref>). For this reason, international safety guidelines require hERG block to be assessed in living cells prior to conducting human trials (<xref ref-type="bibr" rid="c12">ICH Harmonised Tripartite Guideline, 2005</xref>). However, the standard hERG assay is overly sensitive. It does not accommodate multi-channel effects which render some drugs safe despite blocking hERG (<xref ref-type="bibr" rid="c23">Martin et al., 2004</xref>; <xref ref-type="bibr" rid="c10">Hoffmann and Warner, 2006</xref>). Consequently, many useful drugs are prematurely abandoned during pre-clinical trials. The safety pharmacology community are actively pursuing new <italic>in vitro</italic> and <italic>in silico</italic> assays that improve accuracy by targeting multiple ion channels (<xref ref-type="bibr" rid="c33">Pugsley et al., 2008</xref>; <xref ref-type="bibr" rid="c2">Colatsky et al., 2016</xref>).</p>
<p><italic>In silico</italic> assays use computational models of cardiomyocyte electrophysiology in place of a living cell (<xref ref-type="bibr" rid="c24">Mirams et al., 2011</xref>; <xref ref-type="bibr" rid="c17">Lancaster and Sobie, 2016</xref>; <xref ref-type="bibr" rid="c22">Mann et al., 2016</xref>; <xref ref-type="bibr" rid="c3">Dutta et al., 2017</xref>; <xref ref-type="bibr" rid="c32">Passini et al., 2017</xref>; <xref rid="c1a" ref-type="bibr">Ballouz et al., 2020</xref>; <xref ref-type="bibr" rid="c21">Llopis-Lorente et al., 2020</xref>). Drug blockade (<xref rid="fig1" ref-type="fig">Figure 1A</xref>) is simulated in the model (<xref rid="fig1" ref-type="fig">Figure 1B</xref>) by attenuating the conductivity of the relevant ion currents. The conductance parameters are labeled <italic>G</italic> by convention. The simulations can be repeated across a diverse range of cardiac phenotypes to ensure generality of the results (<xref ref-type="bibr" rid="c1">Britton et al., 2013</xref>; <xref ref-type="bibr" rid="c30">Ni et al., 2018</xref>; <xref ref-type="bibr" rid="c4">Gong and Sobie, 2018</xref>). The individual phenotypes are constructed by randomizing the conductance parameters to mimic natural variation in ion channel expression. The method produces a population of cardiac action potentials (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). Selected biomarkers within the action potentials are then statistically analyzed for drug-induced changes (e.g. <xref ref-type="bibr" rid="c11">Hondeghem, 2005</xref>; <xref ref-type="bibr" rid="c38">Varshneya et al., 2021</xref>). Contemporary research is largely concerned with improving those biomarkers.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Conceptual framework.</title>
<p>(<bold>A</bold>) Drugs simultaneously block multiple species of ion channels to differing degrees. The principal ion currents implicated in druginduced Torsades des Pointes are <italic>I</italic><sub>CaL</sub>, <italic>I</italic><sub>Kr</sub>, <italic>I</italic><sub>NaL</sub> and <italic>I</italic><sub>Ks</sub>. (<bold>B</bold>) Simplified circuit diagram of cardiomyocyte electrophysiology. Drug blockade is simulated by attenuating the ionic conductances (<italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>NaL</sub>, <italic>G</italic><sub>Ks</sub>). Those parameters are also varied randomly to mimic individual differences in electrophysiology. (<bold>C</bold>) Simulated action potentials of phenotypically diverse cardiomyocytes. Early after-depolarizations (red) are biomarkers for Torsades des Pointes. Conventional <italic>in silico</italic> assays simulate the effect of drugs on cardiomyocytes on a case by case basis. Our method inverts the procedure by simulating cardiomyocytes in the absence of drugs and then inferring how drugs would behave.</p></caption>
<graphic xlink:href="537441v3_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Yet the main problem with the conventional approach is that it requires multitudes of computationally intensive simulations for every drug that is assessed. Pharmacology laboratories must invest heavily in specialist computing resources and expertise before they can apply the methods to their own drugs. We propose a new approach that allows drugs to be assessed without conducting drug-specific simulations. The method is initiated by simulating a diverse population of cardiomyocytes in the absence of drugs. That simulation need only be done once. The drug-free population is then used to identify the principal relationship between ionic conductances and ectopic phenotypes. We call that relationship the <italic>axis of arrhythmia</italic> because it describes the principal pathway for transforming benign cardiomyocytes into ecoptic cardiomyocytes. Thereafter, the axis serves as a yardstick for assessing the torsadogenic risk of drugs directly from their physiological signature of ion channel blockade alone.</p>
</sec>
<sec id="s2">
<title>Results</title>
<p>The action potentials of 100,000 randomized ventricular cardiomyocytes (<xref rid="fig2" ref-type="fig">Figure 2A</xref>) were simulated using a variant of the O’Hara-Rudy model (<xref ref-type="bibr" rid="c31">O’Hara et al., 2011</xref>) that was optimized for long-QT syndrome (<xref ref-type="bibr" rid="c22">Mann et al., 2016</xref>; <xref ref-type="bibr" rid="c16">Krogh-Madsen et al., 2017</xref>). Early afterdepolarizations were chosen as a biomarker for Torsades des Pointes. Cardiomyocytes that exhibited them were classified as <italic>ectopic</italic> (red) and those t hat d id not were classified as <italic>benign</italic> (gray).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Benign versus ectopic cardiac phenotypes.</title>
<p>(<bold>A</bold>) Simulated action potentials for cardiomyocytes with randomly scaled conductance parameters <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>NaL</sub> and <italic>G</italic><sub>Ks</sub>. Myocytes that exhibited early after-depolarizations were classified as <italic>ectopic</italic> (red). Those that did not were classified as <italic>benign</italic> (gray). (<bold>B</bold>) Swarm plots of the conductance scalars on a logarithmic scale. Color indicates the classification of the myocyte (benign versus ectopic). (<bold>C</bold>) Twodimensional slice of parameter space showing the relationship between ectopic and benign phenotypes in <italic>G</italic><sub>CaL</sub> versus <italic>G</italic><sub>Kr</sub>. The dashed line is the statistical decision boundary. <italic>G</italic><sub>NaL</sub> and <italic>G</italic><sub>Ks</sub> were fixed at unity (<italic>e</italic><sup>0</sup> = 1). (<bold>D</bold>) Twodimensional slice showing <italic>G</italic><sub>NaL</sub> versus <italic>G</italic><sub>Ks</sub>. In this case <italic>G</italic><sub>CaL</sub> is <italic>e</italic><sup>0.46</sup> and <italic>G</italic><sub>Kr</sub> is <italic>e</italic><sup><italic>−</italic>2.3</sup>.</p></caption>
<graphic xlink:href="537441v3_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The four cardiac ion currents that we investigated (<italic>I</italic><sub>CaL</sub>, <italic>I</italic><sub>Kr</sub>, <italic>I</italic><sub>NaL</sub>, <italic>I</italic><sub>Ks</sub>) have previously been implicated in torsadogenic risk (<xref ref-type="bibr" rid="c3">Dutta et al., 2017</xref>; LlopisLorente et al., 2020). The myocytes were constructed by re-scaling the conductance parameters (<italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>NaL</sub>, <italic>G</italic><sub>Ks</sub>) with randomly selected multipliers that were drawn uniformly from a logarithmic scale (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). The use of the logarithmic coordinate frame is crucial to our subsequent analysis.</p>
<p>The ectopic and benign phenotypes were found to be clearly segregated in parameter space (<xref rid="fig2" ref-type="fig">Figures 2C</xref> and <xref ref-type="fig" rid="fig2">2D</xref>). Multivariate logistic regression was used to identify the linear boundary (dashed line) that best separated the two classes. We refer to it as the <italic>decision boundary</italic> following the conventions of classification statistics.</p>
<sec id="s2a">
<title>Decision boundary</title>
<p>The multivariate logistic regression equation,
<disp-formula id="eqn1">
<alternatives><graphic xlink:href="537441v3_eqn1.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
describes the log-odds of a cardiomyocyte being ectopic where <italic>X</italic><sub>CaL</sub> = ln(<italic>G</italic><sub>CaL</sub>), <italic>X</italic><sub>Kr</sub> = ln(<italic>G</italic><sub>Kr</sub>), <italic>X</italic><sub>NaL</sub> = ln(<italic>G</italic><sub>NaL</sub>) and <italic>X</italic><sub>Ks</sub> = ln(<italic>G</italic><sub>Ks</sub>). The decision boundary is the hyperplane in four-dimensional parameter space (<italic>X</italic><sub>CaL</sub>, <italic>X</italic><sub>Kr</sub>, <italic>X</italic><sub>NaL</sub>, <italic>X</italic><sub>Ks</sub>) where <italic>p</italic> = 0.5. <xref rid="fig2" ref-type="fig">Figures 2C</xref> and <xref ref-type="fig" rid="fig2">2D</xref> show the intersection of that hyperplane (dashed) with two-dimensional slices of parameter space. Although we illustrate the concept in two dimensions, the analysis itself is conducted in four dimensions.</p>
<p>Our estimates of the regression coefficients, <italic>β</italic><sub>0</sub> = 6.416±.059, <italic>β</italic><sub>CaL</sub> = 2.509±.024, <italic>β</italic><sub>Kr</sub> =− 2.471± .024, <italic>β</italic><sub>NaL</sub> = 0.847±.012, <italic>β</italic><sub>Ks</sub> = −1.724±.018, were all statistically significant (<italic>p &lt;</italic> .001). The reported confidence intervals represent 1±SE. The model itself was also significantly different from the null model, <italic>χ</italic><sup>2</sup>(99995, <italic>n</italic>=100000) = 73900, <italic>p &lt;</italic> .001.</p>
</sec>
<sec id="s2b">
<title>The action of drugs in logarithmic coordinates</title>
<p>Drugs attenuate the conductivity of ion channels in a multiplicative fashion. The conductance of the drugged channel is defined as,
<disp-formula id="ueqn1">
<alternatives><graphic xlink:href="537441v3_ueqn1.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>G</italic><sub>ion</sub> is the baseline conductance of the ion channel and <italic>δ</italic>∈ [0, 1] is the fractional conductance imposed by the drug. Logarithmic coordinates transform the action of drug blockade into an additive process,
<disp-formula id="ueqn2">
<alternatives><graphic xlink:href="537441v3_ueqn2.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
which can be expressed with vector geometry (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). We denote the action of a drug by the vector,</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Quantifying drug risk with the axis of arrhythmia.</title>
<p><bold>(A)</bold> The axis of arrhythmia runs orthogonally to the decision boundary. As such, it describes the shortest pathway to ectopy for any cardiomyocyte. The action of a drug is represented by <inline-formula><alternatives><inline-graphic xlink:href="537441v3_inline1.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>. The arrhythmogenic component of that drug is <inline-formula><alternatives><inline-graphic xlink:href="537441v3_inline2.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> <italic>R</italic>. It is obtained by projecting <inline-formula><alternatives><inline-graphic xlink:href="537441v3_inline3.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> onto the axis of arrhythmia. The length of <inline-formula><alternatives><inline-graphic xlink:href="537441v3_inline4.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> is our measure of drug risk. <bold>(B)</bold> The cross-sectional profile of the decision boundary along the axis of arrhythmia. The origin corresponds to the baseline cardiomyocyte.</p></caption>
<graphic xlink:href="537441v3_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>
<disp-formula id="ueqn3">
<alternatives><graphic xlink:href="537441v3_ueqn3.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>α</italic> = ln(<italic>δ</italic>). The values of <italic>δ</italic> would ordinarily be obtained from patch-clamp experiments. In our case, we calculated them from the published potencies of 109 drugs collated by <xref ref-type="bibr" rid="c21">Llopis-Lorente et al. (2020)</xref>.</p>
</sec>
<sec id="s2c">
<title>Axis of arrhythmia</title>
<p>We define the axis of arrhythmia as a line that runs orthogonally to the decision boundary (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). It represents the shortest path for shifting any cardiomyocyte into the ectopic regime by modifying the conductances of its ion channels. The basis vector of the axis,
<disp-formula id="ueqn4">
<alternatives><graphic xlink:href="537441v3_ueqn4.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
is defined by the coefficients of the regression equation.</p>
</sec>
<sec id="s2d">
<title>Drug risk metric</title>
<p>The arrhythmogenic component of a drug is obtained by projecting the action of the drug onto the axis of arrhythmia. The length of the projection is our metric of drug risk. Specifically,
<disp-formula id="eqn2">
<alternatives><graphic xlink:href="537441v3_eqn2.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <bold>A</bold> is the action of the drug, <bold>B</bold> is the basis vector of the axis of arrhythmia, and <bold>A·B</bold> = Σ<italic>i α</italic><sub><italic>i</italic></sub><italic>β</italic><sub><italic>i</italic></sub> is the dot product. The metric is normalized to the euclidean length of <bold>B</bold>, which is denoted ║<bold>B</bold>║. For our estimates of the regression coefficients,
<disp-formula id="ueqn5">
<alternatives><graphic xlink:href="537441v3_ueqn5.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
</p>
</sec>
<sec id="s2e">
<title>Risk scores</title>
<p>According to our risk metric, drugs that shift the electrophysiology <italic>towards</italic> the ectopic region have <italic>positive</italic> scores. Conversely, drugs that shift the electrophysiology <italic>away</italic> from ectopy have <italic>negative</italic> scores. Drugs that do neither have scores near zero.</p>
</sec>
<sec id="s2f">
<title>The <italic>a priori</italic> probability of ectopy</title>
<p>The probability of ectopy along the axis of arrhythmia is,
<disp-formula id="eqn3">
<alternatives><graphic xlink:href="537441v3_eqn3.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>x</italic> = <italic>β</italic><sub>0</sub> + <italic>β</italic><sub>CaL</sub><italic>X</italic><sub>CaL</sub> + <italic>β</italic><sub>Kr</sub><italic>X</italic><sub>Kr</sub> + <italic>β</italic><sub>NaL</sub><italic>X</italic><sub>NaL</sub> + <italic>β</italic><sub>Ks</sub><italic>X</italic><sub>Ks</sub>. <xref ref-type="disp-formula" rid="eqn3">Eq. (3)</xref> is obtained by rearranging <xref ref-type="disp-formula" rid="eqn1">Eq. (1)</xref>. It describes the cross-sectional profile of the decision boundary (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). As such, it represents the <italic>a priori</italic> probability of a cardiomyocyte being ectopic, on average, based on its proximity to the decision boundary. The shallow slope of the profile is indicative of the statistical uncertainty in fitting a linear boundary to the data points (<xref rid="fig2" ref-type="fig">Figures 2C,D</xref>).</p>
</sec>
<sec id="s2g">
<title>Susceptibility in the natural population</title>
<p>A drug alters the electrophysiology of all cardiomyocytes to the same extent but only some cardiomyocytes become ectopic. The most susceptible are those that are closest to the decision boundary. We calculated the proportion of the natural population that would be susceptible to a given drug by analyzing how the drug shifts the population density with respect to the decision boundary.</p>
<p>Following the methods of <xref ref-type="bibr" rid="c36">Sobie (2009)</xref>, <xref ref-type="bibr" rid="c34">Sadrieh et al. (2013)</xref>, <xref ref-type="bibr" rid="c29">Morotti and Grandi (2017)</xref>, <xref ref-type="bibr" rid="c4">Gong and Sobie (2018)</xref> we assumed that ion channel conductances varied independently in nature and were log-normally distributed (<italic>μ</italic> = − 0.112, <italic>σ</italic> = 0.472). By definition, a lognormal distribution maps onto a normal distribution in logarithmic coordinates. The natural population in our parameter space is therefore a symmetric multivariate Gaussian density function (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). In the absence of drugs, the natural population density in four dimensions is centered at the point <bold>O</bold> = {<italic>μ, μ, μ, μ</italic>}.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Susceptibility to a drug in the natural population.</title>
<p><bold>(A)</bold> Natural variation in ion channel conductivity is represented by a symmetric Gaussian density function centered at point <bold>O</bold>. In this example, a tenfold dose of Ibutilide shifts the population by 1.44 units towards the ecoptic region. The proportion of ectopic myocytes in the drugged population is 41.5% (red). <bold>(B)</bold> The relationship between the drug risk score and ectopy in the natural population. The drug risk score corresponds to position on the axis of arrhythmia. The shaded region is the <italic>a priori</italic> probability of ectopy along that axis (reproduced from <xref ref-type="fig" rid="fig3">Figure 3B</xref>). The Gaussian profile (thin gray line) is the natural population density centered at zero. The proportion of myocytes that are ectopic (heavy black line) is 0.93% at baseline. That proportion rises as the drug shifts the population density towards the decision boundary. See Supplementary Video SV1 for an animated version.</p></caption>
<graphic xlink:href="537441v3_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The proportion of myocytes that become ectopic depends on how far the population is shifted along the axis of arrhythmia according to the risk metric (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). The proportion is calculated as the product of the <italic>a priori</italic> probability of the ectopy (<xref ref-type="disp-formula" rid="eqn3">Eq. 3</xref>) and the density of the drugged population (<xref ref-type="disp-formula" rid="eqn5">Eq. 5</xref>; Methods). For the case of 10x therapeutic dose of Ibutilide — a potent blocker of <italic>I</italic><sub>Kr</sub> — the proportion of the natural population that is susceptible to drug-induced Torsades is 41.5% (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Since the size of the susceptible population is monotonically related to the drug’s risk score, the torsadogenic risk can be described using either terminology.</p>
</sec>
<sec id="s2h">
<title>Validation against known drugs</title>
<p>We used the Hill equation to reconstruct the drugresponse profiles of <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>Ks</sub> and <italic>G</italic><sub>NaL</sub> from the half-maximal inhibitory concentrations (<italic>IC</italic><sub>50</sub>) of 109 drugs reported by <xref ref-type="bibr" rid="c21">Llopis-Lorente et al., 2020</xref>. The results for each drug are included in the Supplementary Information. <xref ref-type="bibr" rid="c21">Llopis-Lorente et al. (2020)</xref> labeled the clinical risks according to the Credible Meds list of QT drugs (<xref ref-type="bibr" rid="c40">Woosley et al., 2019</xref>). In that labeling scheme, Class 1 drugs carry a known torsadogenic risk; Class 2 drugs carry a possible risk; Class 3 drugs carry a risk but only in conjunction with other factors; Class 4 drugs have no evidence of risk at all.</p>
</sec>
<sec id="s2i">
<title>Cases of Ajmaline and Linezolid</title>
<p>Ajmaline is an anti-arrhythmic drug that primarily blocks the fast sodium current (<xref ref-type="bibr" rid="c13">Kiesecker et al., 2004</xref>). Clinicians must administer Ajmaline with care because it is also a potent blocker of <italic>I</italic><sub>Kr</sub> (<xref rid="fig5" ref-type="fig">Figure 5A</xref>, left) with a known risk of Torsades (Class 1). In comparison, Linezolid is an antibacterial agent that has no clinical evidence of Torsades (Class 4) even though it too blocks <italic>I</italic><sub>Kr</sub>. Albeit less than it blocks <italic>I</italic><sub>CaL</sub> (<xref rid="fig5" ref-type="fig">Figure 5A</xref>, right).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Cases of Ajmaline and Linezolid.</title>
<p><bold>(A)</bold> Drug response profiles of <italic>I</italic><sub>CaL</sub>, <italic>I</italic><sub>Kr</sub>, <italic>I</italic><sub>NaL</sub> and <italic>I</italic><sub>Ks</sub> relative to the therapeutic dose. Open circles highlight 25x therapeutic dose. Ajmaline has <italic>δ</italic><sub>CaL</sub> = 0.654 and <italic>δ</italic><sub>Kr</sub> = 0.0986 at 25x dose, whereas Linezolid has <italic>δ</italic><sub>CaL</sub> = 0.067 and <italic>δ</italic><sub>Kr</sub> = 0.437. Data for <italic>I</italic><sub>NaL</sub> and <italic>I</italic><sub>Ks</sub> were not available, so they were assumed to be unaffected (<italic>δ</italic><sub>NaL</sub> = 1 and <italic>δ</italic><sub>Ks</sub> = 1). <bold>(B)</bold> The blocking action of Ajmaline and Linezolid at 25x dose. Drug action is defined as <italic>α</italic> = ln(<italic>δ</italic>). <bold>(C)</bold> The corresponding risk scores for Ajmaline (+1.16) and Linezolid (<italic>−</italic>1.18) at that dose. <bold>(E)</bold> The drug-induced shifts of the natural population density along the axis of arrhythmia. The proportion of myocytes that are ectopic with 25x dose of Ajmaline is 26% (red), compared to only 0.0095% for Linezolid.</p></caption>
<graphic xlink:href="537441v3_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Indeed, the two drugs have nearly opposite effects on <italic>G</italic><sub>CaL</sub> and <italic>G</italic><sub>Kr</sub>, as can be seen in the case of 25x therapeutic dose (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). Using vector notation, the blocking action of 25x dose of Ajmaline is,
<disp-formula id="ueqn6">
<alternatives><graphic xlink:href="537441v3_ueqn6.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
and the blocking action of Linezolid is,
<disp-formula id="ueqn7">
<alternatives><graphic xlink:href="537441v3_ueqn7.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
The two drugs shift the electrophysiology in opposite directions along the axis of arrhythmia (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). The corresponding risk scores are +1.16 for Ajmaline and − 1.18 for Linezolid. The signs of the scores suggest that Ajmaline is pro-arrhythmic whereas Linezolid is not, which agrees with the clinical risk labels. Indeed, the sizable negative score for Linezolid suggests that it may actually have anti-arrhythmic properties.</p>
<p>The effect of both drugs on the natural population is shown in <xref rid="fig5" ref-type="fig">Figure 5D</xref>. Ajmaline shifts the population density by 1.16 units towards the ectopic regime, which suggests that 26% of the recipients would be susceptible to Torsades. Conversely, Linezolid shifts the population 1.18 units away from the ectopic regime. So only 0.0095% of those who received Linezolid would be susceptible. A substantial drop from the baseline rate of 0.93%.</p>
</sec>
<sec id="s2j">
<title>Drug action varies with dose</title>
<p>The direction of a drug’s line of action is liable to vary with dosage because of differential binding to each ion channel. For example, Ajmaline disproportionately blocks more <italic>I</italic><sub>Kr</sub> than <italic>I</italic><sub>CaL</sub> with increasing dosage (<xref rid="fig6" ref-type="fig">Figure 6A</xref>). Hence the pathway of Ajmaline follows a gentle arc in parameter space rather than a straight line (<xref rid="fig6" ref-type="fig">Figure 6B</xref>). The effect is less pronounced for Propafenone which recruits the ion channels more uniformly (<xref rid="fig6" ref-type="fig">Figure 6C</xref>). Nonetheless, its path is still not strictly linear (<xref rid="fig6" ref-type="fig">Figure 6D</xref>). Linezolid follows a similar pattern to Ajmaline but in the opposite direction (<xref rid="fig6" ref-type="fig">Figures 6E</xref> and <xref ref-type="fig" rid="fig6">6F</xref>). In general, the pathways of all 109 drugs (light gray traces) exhibited a variety of curvatures that influence their projection onto the axis of arrhythmia. Consequently the relative scores of some drugs change subtly with dosage.</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Figure 6.</label>
<caption><title>The effect of multi-channel block changes with dosage.</title>
<p><bold>(A)</bold> The attenuation of <italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>NaL</sub> and <italic>G</italic><sub>Ks</sub> by Ajmaline over a range of doses. <bold>(B)</bold> The action of Ajmaline in parameter space. Gray traces are the pathways of all 109 drugs that we investigated. <bold>(C-D)</bold> Propafenone. <bold>(E-F)</bold> Linezolid.</p></caption>
<graphic xlink:href="537441v3_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2k">
<title>Testing the risk metric</title>
<p>The metric was tested by scoring all 109 drugs over a range of doses and comparing the results to the clinical risk labels from Credible Meds. The clinical labels were lumped into two categories for this purpose: UNSAFE (class 1 and 2) versus SAFE (class 3 and 4). Drugs that scored above a given threshold (risk <italic>&gt; θ</italic>) were predicted to be UNSAFE and those that scored below the threshold (risk <italic>&lt; θ</italic>) were predicted to be SAFE. The threshold was optimized for each dosage. For drugs assessed at 25x dose, a classification accuracy of 90.8% was achieved using a scoring threshold of <italic>θ</italic> = 0.195 (<xref rid="fig7" ref-type="fig">Figure 7</xref>).</p>
<fig id="fig7" position="float" fig-type="figure">
<label>Figure 7.</label>
<caption><title>Torsadogenic risk for 109 drugs at 25x dose.</title>
<p>Colors indicate the clinical risk labels from Credible Meds. The drugs are sorted by the score returned by our risk metric (lower axis). The proportion of the natural population that would be susceptible to the drug is shown on the upper axis. Drugs to the right of the scoring threshold (<italic>θ</italic> = 0.195) were classified as UNSAFE and those to the left of it were classified as SAFE. Misclassified drugs are marked with a triangle and highlighted in bold. In this case, 90.8% of the drugs were correctly classified.</p></caption>
<graphic xlink:href="537441v3_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The procedure was repeated for doses ranging from 1x to 32x. The classification accuracy for all dosage levels was found to lay between 88.1% and 90.8% (<xref rid="fig8" ref-type="fig">Figure 8A</xref>). The differences were primarily due to classification errors in a small number of borderline cases. So we refrain from nominating any one dosage as being optimal. The conventional hERG assay, in comparison, has an accuracy of 78.9% with the same dataset (LlopisLorente et al., 2020).</p>
<fig id="fig8" position="float" fig-type="figure">
<label>Figure 8.</label>
<caption><title>Optimal dosage.</title>
<p><bold>(A)</bold> Classification accuracy for drugs assessed at a range of dosages. <bold>(A)</bold> ROC curve for drugs at 5x dose. <bold>(B)</bold> ROC curve for drugs at 25x dose. AUROC is area under the ROC curve. TPR is true positive rate. FPR is false positive rate. The false negative rate is 1-TPR.</p></caption>
<graphic xlink:href="537441v3_fig8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>From a safety perspective, the trade-off between false negatives and false positives can be tuned by adjusting the scoring threshold, <italic>θ</italic>. This is illustrated by the Receiver Operating Characteristic (ROC) curves (<xref rid="fig8" ref-type="fig">Figures 8B</xref> and <xref ref-type="fig" rid="fig8">8C</xref>). In our case, there is little difference between the ROC curves for drugs assessed at 5x dose versus 25x dose. The area under the ROC curves (AU-ROC) are nearly identical at 91.3% and 91.5% respectively. In comparison, the conventional hERG assay has an AUROC of 77 ± 7% (<xref ref-type="bibr" rid="c14">Kramer et al., 2013</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>In this study we have proposed a new metric of torsadogenic risk that is based on the axis of arrhythmia. The major benefit of the metric is that it can be applied to novel drugs without conducting any new computer simulations. The drug response profiles of four ion currents (<italic>δ</italic><sub>CaL</sub>, <italic>δ</italic><sub>Kr</sub>, <italic>δ</italic><sub>NaL</sub>, <italic>δ</italic><sub>Ks</sub>) are all that is needed to calculate the torsadogenic risk of the drug. The ion currents can be measured using standard patch clamp techniques and the risk metric can be calculated with pen and paper. This simplicity removes a technological hurdle to the adoption of computational assays in safety pharmacology.</p>
<sec id="s3a">
<title>Identifying the axis of arrhythmia</title>
<p>All of the simulations in the present study were conducted in the absence of drugs. They were only needed to identify the axis of arrhythmia and do not need to be repeated when applying the metric. The axis encapsulates the linear relationship between the four ion channels and the onset of early after-depolarizations. It corresponds to the most potent combination of proarrhythmic drug block that is theoretically possible. The assumption of linearity is crucial for averaging the risk across all individuals. So even though a nonlinear decision boundary might fit the data better, it would not be helpful because the results would be patient specific.</p>
</sec>
<sec id="s3b">
<title>Susceptibility to drug-induced arrhythmia</title>
<p>Our method can also predict the proportion of the population that would be susceptible to a drug without explicitly simulating it. The analysis is possible because drug blockade and natural diversity both operate on the same properties of ion channels. The two biological processes are therefore mathematically interchangeable. As such, the distribution of the drugged population can be inferred from the drug-free population by shifting it according to the drug’s risk score. The size of the susceptible population is a function of the risk score. So the torsadogenic risk can be reported either as a raw score or as a percentage of the population at risk.</p>
</sec>
<sec id="s3c">
<title>Comparison to conventional approaches</title>
<p>Conventional <italic>in silico</italic> safety assays are designed to apply the drug directly to simulated cardiomyocytes and then use biomarkers in the action potential to predict the torsadogenic risk. See <xref ref-type="bibr" rid="c5">Grandi et al. (2018)</xref> for a review. The predictions are optimized for established drugs using a training procedure that has been formalized by the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative (<xref ref-type="bibr" rid="c2">Colatsky et al., 2016</xref>). The CiPA steering committee (<xref ref-type="bibr" rid="c20">Li et al., 2019</xref>) recommends the CiPAORdv1.0 variant of the O’Hara-Rudy model which incorporates the kinetics of drugs binding with the hERG channel (<xref ref-type="bibr" rid="c19">Li et al., 2017</xref>). The recommended biomarker is qNet (<xref ref-type="bibr" rid="c3">Dutta et al., 2017</xref>) which measures the net charge of six major ion currents (<italic>I</italic><sub>Kr</sub>, <italic>I</italic><sub>CaL</sub>, <italic>I</italic><sub>NaL</sub>, <italic>I</italic><sub>to</sub>, <italic>I</italic><sub>Ks</sub>, <italic>I</italic><sub>K1</sub>). The clinical risks of the CiPA drugs (n=28) are labeled low, intermediate or high. <italic>Low</italic> versus <italic>intermediate-or-high</italic> risk drugs were predicted with 84–95% accuracy using manual patch clamp techniques; or 93-100% accuracy using automated patch clamping (<xref ref-type="bibr" rid="c20">Li et al., 2019</xref>). Whereas <italic>low-or-intermediate</italic> versus <italic>high</italic> risk drugs were predicted to 92–100% accuracy using manual patch clamp; or 88-98% using automated patch clamp (<xref ref-type="bibr" rid="c20">Li et al., 2019</xref>). The measurement of the drug potencies is a source of considerable variability, which is exacerbated by the small number of test drugs (n=16). The accuracy ranges reported by <xref ref-type="bibr" rid="c20">Li et al. (2019)</xref> appear to outperform our results, although they cannot be compared directly because the risk labels are stratified very differently.</p>
<p><xref ref-type="bibr" rid="c32">Passini et al. (2017)</xref> used a larger dataset (n=62) to obtain 89% accuracy at predicting class 1 versus class 2–4 torsadogenic risk labels from Credible Meds. The cardiomyocytes were simulated using the baseline O’HaraRudy model without dynamic drug-binding kinetics. The accuracy is within the range of our results, albeit using a slightly different risk stratification scheme. <xref ref-type="bibr" rid="c32">Passini et al. (2017)</xref> scored the torsadogenic risk independently of dosage by averaging number of early afterdepolarizations, weighted by the concentration of the drug. However we believe it is better to quantify the risk as a function of dosage, since even the most lethal drug is safe at zero dose.</p>
<p>The present study uses the same dataset (n=109) as <xref ref-type="bibr" rid="c21">Llopis-Lorente et al. (2020)</xref> who investigated a suite of biomarkers using a recalibrated O’Hara-Rudy model which also had revised gating kinetics for <italic>I</italic><sub>Na</sub>. Their best performing biomarker was qNet, which predicted class 1–2 versus class 3–4 torsadogenic risk with 92.7% accuracy. It exceeds our best result by approximately 2% on the same risk stratification scheme. LlopisLorente et al. (2020) increased the overall performance to 94.5% by combining the best biomarkers into a decision tree. Interestingly, early after-depolarizations proved to be their worst biomarker with only 78.9% accuracy. Based on our analysis, it is likely they undersampled the early after-depolarizations by constraining their cardiomyocytes to normal physiological limits.</p>
</sec>
<sec id="s3d">
<title>Comparison to MICE models</title>
<p>MICE models (<xref ref-type="bibr" rid="c14">Kramer et al., 2013</xref>) use logistic regression to predict the torsadogenic risk of a drug directly from the half maximal inhibitory concentrations (<italic>IC</italic><sub>50</sub>) for hERG, Cav1.2 and Nav1.5. They are derived using statistical model fitting techniques. <xref ref-type="bibr" rid="c14">Kramer et al. (2013)</xref> trained six candidate models on a dataset of 55 drugs. Their best model was found to predict the torsadogenic labels of the drugs with 90.9% accuracy using only the difference between hERG and Cav1.2. Specifically,
<disp-formula id="ueqn8">
<alternatives><graphic xlink:href="537441v3_ueqn8.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>H</italic>= − ln(<italic>IC</italic><sub>50</sub>) for hERG, and <italic>C</italic> = − ln(<italic>IC</italic><sub>50</sub>) for Cav1.2. The form of the predictor variables are strikingly similar to our own except that we use the fractional conductance (<italic>δ</italic>) instead of <italic>IC</italic><sub>50</sub>. In our case, the predictors were derived from biophysical principals of drug block rather than through statistical model fitting. The accuracy of the two models are nearly identical, albeit on different datasets.</p>
</sec>
<sec id="s3e">
<title>Comparison to Bnet</title>
<p>Bnet (<xref ref-type="bibr" rid="c27">Mistry, 2018</xref>) is a simple linear model that predicts the torsadogenic risk of a drug directly from the net blockade of inward and outward ion currents. Notably,
<disp-formula id="ueqn9">
<alternatives><graphic xlink:href="537441v3_ueqn9.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>R</italic><sub><italic>i</italic></sub> and <italic>D</italic><sub><italic>j</italic></sub> represent the percentage block of the repolarizing currents (<italic>I</italic><sub>Kr</sub>, <italic>I</italic><sub>Ks</sub>, <italic>I</italic><sub>to</sub>) and the depolarizing currents (<italic>I</italic><sub>CaL</sub>, <italic>I</italic><sub>Na</sub>, <italic>I</italic><sub>NaL</sub>, <italic>I</italic><sub>K1</sub>) respectively. Percentage block is akin to (1 −<italic>δ</italic>) in our model but without the logarithmic transform that we use to analyze attenuation as an additive process. Bnet predicts the clinical risk labels of the CiPA validation drugs just as well as the CiPAORdv1.0 model when adjusted for drug binding kinetics (<xref ref-type="bibr" rid="c20">Li et al., 2019</xref>; <xref ref-type="bibr" rid="c28">Mistry, 2019</xref>; <xref ref-type="bibr" rid="c6">Han et al., 2019</xref>). This has opened a debate between model complexity and biophysical realism in which proponents of biophysical models advocate their explanatory benefits (<xref ref-type="bibr" rid="c18">Lancaster and Sobie, 2017</xref>), whereas proponents of simple models advocate their predictive power without the computational expense (<xref ref-type="bibr" rid="c25">Mistry et al., 2015</xref>; <xref ref-type="bibr" rid="c26">Mistry, 2017</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>Conclusion</title>
<p>Our approach resolves the debate between model complexity and biophysical realism by combining both approaches into the same enterprise. The method is initiated using biophysical models to explore the relationship between ion channels and torsadogenic risk — as it is best understood by theory. The findings are then condensed into a simple linear model that can be applied without recapitulating the biophysical details. That is not to say the linear model is mere statistical correlation. It still represents the biophysical action of multichannel drug blockade but only as far as it relates to early after-depolarizations. Our approach thus represents a convergence of biophysical and simple models. One that provides the benefits of biophysical modeling without the computational burden. We believe it will accelerate the adoption of computational assays in safety pharmacology and ultimately reduce the burden of animal testing.</p>
</sec>
<sec id="s5">
<title>Methods</title>
<p>The action potentials of human endocardial ventricular cardiomyocytes were simulated using a variant of the ORD11 model (<xref ref-type="bibr" rid="c31">O’Hara et al., 2011</xref>) in which the maximal conductances of <italic>G</italic><sub>Ks</sub>, <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>NaL</sub>, <italic>P</italic><sub>NaCa</sub> and <italic>P</italic><sub>NaK</sub> were re-scaled (<xref rid="tbl1" ref-type="table">Table 1</xref>) to better reproduce the clinical phenotypes of long QT syndrome (<xref ref-type="bibr" rid="c22">Mann et al., 2016</xref>; <xref ref-type="bibr" rid="c16">Krogh-Madsen et al., 2017</xref>). The source code for the ORD11 model (<xref ref-type="bibr" rid="c31">O’Hara et al., 2011</xref>) was adapted to run in the Brain Dynamics Toolbox (<xref ref-type="bibr" rid="c8">Heitmann et al., 2018</xref>; <xref ref-type="bibr" rid="c7">Heitmann and Breakspear, 2022</xref>). The adapted source code is available from <xref ref-type="bibr" rid="c9">Heitmann (2023)</xref>. The differential equations were integrated forward in time using the matlab ode15s solver with error tolerances AbsTol=1e-3 and RelTol=1e-6. The model was paced at 1 Hz with a stimulus of -70 mV and duration of 0.5 ms. All simulations were equilibrated for at least 1000 beats prior to analysis.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>The baseline scaling factors applied to the ORD11 model.</p></caption>
<graphic xlink:href="537441v3_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<sec id="s5a">
<title>Classification of ectopic phenotypes</title>
<p>Blocks of four successive beats were analyzed to accommodate alternans. Cells were classified a s ectopic if any of those four beats contained an early afterdepolarization — as defined by any secondary peak that rose above -50 mV and was separated from other peaks by at least 100 ms. Cells that did not exhibit early afterdepolarizations were classified as benign.</p>
</sec>
<sec id="s5b">
<title>Parameter domain</title>
<p>We chose the domain of parameter space (<italic>G e</italic><sup><italic>±</italic>3</sup>) using trial and error. The domain must be large enough to cover the ectopic region but not so large as to be unduly influenced by biological e xtremes. Our chosen domain spans conductances between 0.05 and 20 times their baseline value.</p>
</sec>
<sec id="s5c">
<title>Natural population density</title>
<p>Cell-to-cell variability was mimicked by scaling the conductances (<italic>G</italic><sub>CaL</sub>, <italic>G</italic><sub>Kr</sub>, <italic>G</italic><sub>NaL</sub>, <italic>G</italic><sub>Ks</sub>) by a random multiplier that was drawn from a log-normal distribution (<xref ref-type="bibr" rid="c36">Sobie, 2009</xref>). The parameters of the distribution (<italic>μ</italic>=0.112, <italic>σ</italic> = 0.472) were chosen to give the multipliers a mean of 1 and standard deviation of 0.5. The spread was based on our experience with previous simulations (<xref ref-type="bibr" rid="c34">Sadrieh et al., 2013</xref>, <xref ref-type="bibr" rid="c35">2014</xref>; <xref rid="c1a" ref-type="bibr">Ballouz et al., 2020</xref>; <xref ref-type="bibr" rid="c37">TeBay et al., 2022</xref>). The four ion channel species were assumed to vary independently.</p>
<p>By definition, the log-normal distribution maps onto the normal distribution under the logarithmic transform. The natural population was therefore represented in logarithmic parameter space by a symmetric multivariate normal distribution. Specifically,
<disp-formula id="ueqn10">
<alternatives><graphic xlink:href="537441v3_ueqn10.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
Where
<disp-formula id="eqn4">
<alternatives><graphic xlink:href="537441v3_eqn4.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
is the univariate normal distribution.</p>
</sec>
<sec id="s5d">
<title>Joint probability</title>
<p>Rotational symmetry allowed the multivariate distribution to be projected onto the axis of arrhythmia as a univariate distribution. The probability of a cardiomyocyte in the natural population being ectopic is,
<disp-formula id="eqn5">
<alternatives><graphic xlink:href="537441v3_eqn5.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>p</italic>(<italic>x</italic>) is the <italic>a priori</italic> probability of ectopy for that phenotype (<xref ref-type="disp-formula" rid="eqn3">Eq. 3</xref>) and <italic>f</italic> (<italic>x</italic>) is the proportion of cells in the population with that phenotype (<xref ref-type="disp-formula" rid="eqn4">Eq. 4</xref>). Drugs serve to shift <italic>f</italic> (<italic>x</italic>) along the axis of arrhythmia. The size of that shift is defined by the risk metric (<xref ref-type="disp-formula" rid="eqn2">Eq. 2</xref>).</p>
</sec>
<sec id="s5e">
<title>Drug dataset</title>
<p>The drug response curves were reconstructed using the Hill equation,
<disp-formula id="ueqn11">
<alternatives><graphic xlink:href="537441v3_ueqn11.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where <italic>δ</italic>∈ [0, 1] represents the fractional conductance of the ion channel. The concentration of the drug (<italic>C</italic>) was normalized to the effective free therapeutic plasma concentration (EFTPC). The Hill coefficient was fixed at <italic>h</italic> = 1 on the assumption that single drug molecules bound to the ion channels independently. The half-maximal inhibitory concentrations (<italic>IC</italic><sub>50</sub>) were taken from Supplementary Table S2 of <xref ref-type="bibr" rid="c21">Llopis-Lorente et al. (2020)</xref>. That data was curated from multiple public databases and scientific publications to ameliorate the effects of crosssite and cross-platform variability (<xref ref-type="bibr" rid="c15">Kramer et al., 2020</xref>). The dataset uses the median <italic>IC</italic><sub>50</sub> for cases where multiple values were reported (<xref ref-type="bibr" rid="c21">Llopis-Lorente et al., 2020</xref>). Similarly, it uses the highest therapeutic dosage for cases where multiple EFTPCs were reported (LlopisLorente et al., 2020). Ion channels with missing IC<sub>50</sub> values were assumed not to be blocked by the drug (<italic>δ</italic> = 1). The reconstructed response curves are given in Supplementary Dataset S1. The clinical risk labels for the drugs were transcribed from <xref rid="tbl1" ref-type="table">Table 1</xref> of LlopisLorente et al. (2020).</p>
</sec>
</sec>
<sec id="d1e1666" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e1746">
<label>Supplementary Video SV1</label>
<media xlink:href="supplements/537441_file02.mp4"/>
</supplementary-material>
<supplementary-material id="d1e1753">
<label>Supplementary Dataset S1</label>
<media xlink:href="supplements/537441_file03.csv"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was supported by Australian NHMRC grants app1182032, app1182623 and NSW Health cardiovascular capacity building grant. SH was also funded by The Medical Advances Without Animals Trust (MAWA). The aim of MAWA is to advance medical science and improve human health and therapeutic interventions without the use of animals or animal products. This research includes computations using the computational cluster Katana supported by Research Technology Services at UNSW Sydney.</p>
</ack>
<ref-list>
<ref id="c1a"><mixed-citation publication-type="journal"><string-name><surname>Ballouz</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mangala</surname>, <given-names>M. M.</given-names></string-name>, <string-name><surname>Perry</surname>, <given-names>M. D.</given-names></string-name>, <string-name><surname>Heitmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gillis</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A. P.</given-names></string-name>, and <string-name><surname>Vandenberg</surname>, <given-names>J. I.</given-names></string-name> <article-title>Co-expression of calcium and hERG potassium channels reduces the incidence of proarrhythmic events</article-title>. <source>Cardiovascular Research, (cvaa280)</source>, <month>Oct</month>. <year>2020</year>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvaa280</pub-id>.</mixed-citation></ref>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Britton</surname>, <given-names>O. J.</given-names></string-name>, <string-name><surname>Bueno-Orovio</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Van Ammel</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>H. R.</given-names></string-name>, <string-name><surname>Towart</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Gallacher</surname>, <given-names>D. J.</given-names></string-name>, and <string-name><surname>Rodriguez</surname>, <given-names>B.</given-names></string-name> <article-title>Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology</article-title>. <source>PNAS</source>, <volume>110</volume>(<issue>23</issue>):<fpage>E2098</fpage>–<lpage>E2105</lpage>, <month>June</month> <year>2013</year>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1304382110</pub-id>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Colatsky</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Fermini</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Gintant</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Pierson</surname>, <given-names>J. B.</given-names></string-name>, <string-name><surname>Sager</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Sekino</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Strauss</surname>, <given-names>D. G.</given-names></string-name>, and <string-name><surname>Stockbridge</surname>, <given-names>N.</given-names></string-name> <article-title>The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress</article-title>. <source>J Pharmacol Toxicol Methods</source>, <volume>81</volume>:<fpage>15</fpage>–<lpage>20</lpage>, <month>Sept</month>. <year>2016</year>. doi: <pub-id pub-id-type="doi">10.1016/j.vascn.2016.06.002</pub-id>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Dutta</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>K. C.</given-names></string-name>, <string-name><surname>Beattie</surname>, <given-names>K. A.</given-names></string-name>, <string-name><surname>Sheng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tran</surname>, <given-names>P. N.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>W. W.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Strauss</surname>, <given-names>D. G.</given-names></string-name>, <string-name><surname>Colatsky</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Li</surname>, <given-names>Z.</given-names></string-name> <article-title>Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment</article-title>. <source>Front Physiol</source>, <volume>8</volume>:<fpage>616</fpage>, <year>2017</year>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2017.00616</pub-id>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="book"><string-name><surname>Gong</surname>, <given-names>J. Q. X.</given-names></string-name> and <string-name><surname>Sobie</surname>, <given-names>E. A.</given-names></string-name> <chapter-title>Population-based mechanistic modeling allows for quantitative predictions of drug responses across cell types</chapter-title>. <source>NPJ Syst Biol Appl</source>, <volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>, <month>Feb</month>. <year>2018</year>. doi: <pub-id pub-id-type="doi">10.1038/s41540-018-0047-2</pub-id>. Number: 1 Publisher: <publisher-name>Nature Publishing Group</publisher-name>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="other"><string-name><surname>Grandi</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Morotti</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pueyo</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Rodriguez</surname>, <given-names>B.</given-names></string-name>, editors. <article-title>Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond</article-title>. <source>Frontiers Research Topics. Frontiers Media SA</source>, <year>2018</year>. ISBN <isbn>978-2-88945-539-3</isbn>. doi: <pub-id pub-id-type="doi">10.3389/978-2-88945-539-3</pub-id>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Han</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>K.-S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>H.-A.</given-names></string-name>, and <string-name><surname>Yim</surname>, <given-names>D.-S.</given-names></string-name> <article-title>Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs</article-title>. <source>Front Pharmacol</source>, <volume>10</volume>, <year>2019</year>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="other"><string-name><surname>Heitmann</surname>, <given-names>S.</given-names></string-name> and <string-name><surname>Breakspear</surname>, <given-names>M.</given-names></string-name> <source>Handbook for the Brain Dynamics Toolbox: Version 2022</source>. bdtoolbox.org, 7th edition, <year>2022</year>. ISBN <isbn>978-0-645-06692-01</isbn>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Heitmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Aburn</surname>, <given-names>M. J.</given-names></string-name>, and <string-name><surname>Breakspear</surname>, <given-names>M.</given-names></string-name> <article-title>The Brain Dynamics Toolbox for Matlab</article-title>. <source>Neurocomputing</source>, <volume>315</volume>:<fpage>82</fpage>–<lpage>88</lpage>, <month>Nov</month>. <year>2018</year>. doi: <pub-id pub-id-type="doi">10.1016/j.neucom.2018.06.026</pub-id>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="web"><string-name><surname>Heitmann</surname>, <given-names>S.</given-names></string-name> <source>Source code for simulating the O’Hara-Rudy (ORd) model of the human cardiac action potential in the Brain Dynamics Toolbox</source>, <month>Apr</month>. <year>2023</year>. URL <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/7796721">https://zenodo.org/record/7796721</ext-link>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Hoffmann</surname>, <given-names>P.</given-names></string-name> and <string-name><surname>Warner</surname>, <given-names>B.</given-names></string-name> <article-title>Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends</article-title>. <source>J Pharmacol Toxicol Methods</source>, <volume>53</volume>(<issue>2</issue>):<fpage>87</fpage>–<lpage>105</lpage>, <month>Mar</month>. <year>2006</year>. doi: <pub-id pub-id-type="doi">10.1016/j.vascn.2005.07.003</pub-id>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="book"><string-name><surname>Hondeghem</surname>, <given-names>L. M.</given-names></string-name> <chapter-title>TRIad: Foundation for Proarrhythmia (Triangulation, Reverse Use Depen-dence and Instability</chapter-title>). <source>In The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome</source>, pages <fpage>235</fpage>–<lpage>250</lpage>. <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>, <year>2005</year>. ISBN <isbn>978-0-470-02142-2</isbn>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="other"><collab>ICH Harmonised Tripartite Guideline</collab>. <source>The non-clinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals S7B</source>. <year>2005</year>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Kiesecker</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zitron</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Lück</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bloehs</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Scholz</surname>, <given-names>E. P.</given-names></string-name>, <string-name><surname>Kathöfer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Kreye</surname>, <given-names>V. A. W.</given-names></string-name>, <string-name><surname>Katus</surname>, <given-names>H. A.</given-names></string-name>, <string-name><surname>Schoels</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Karle</surname>, <given-names>C. A.</given-names></string-name>, and <string-name><surname>Kiehn</surname>, <given-names>J.</given-names></string-name> <article-title>Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action</article-title>. <source>Naunyn-Schmiedeberg’s Arch Pharmacol</source>, <volume>370</volume>(<issue>6</issue>):<fpage>423</fpage>–<lpage>435</lpage>, <month>Dec</month>. <year>2004</year>. doi: <pub-id pub-id-type="doi">10.1007/s00210-004-0976-8</pub-id>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Kramer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Obejero-Paz</surname>, <given-names>C. A.</given-names></string-name>, <string-name><surname>Myatt</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Kuryshev</surname>, <given-names>Y. A.</given-names></string-name>, <string-name><surname>Bruening-Wright</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Verducci</surname>, <given-names>J. S.</given-names></string-name>, and <string-name><surname>Brown</surname>, <given-names>A. M.</given-names></string-name> <article-title>MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes</article-title>. <source>Sci Rep</source>, <volume>3</volume>(<issue>1</issue>):<fpage>2100</fpage>, <month>Dec</month>. <year>2013</year>. doi: <pub-id pub-id-type="doi">10.1038/srep02100</pub-id>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="book"><string-name><surname>Kramer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Himmel</surname>, <given-names>H. M.</given-names></string-name>, <string-name><surname>Lindqvist</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Stoelzle-Feix</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chaudhary</surname>, <given-names>K. W.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Bohme</surname>, <given-names>G. A.</given-names></string-name>, <string-name><surname>Bridgland-Taylor</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hebeisen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Fan</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Renganathan</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Imredy</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Humphries</surname>, <given-names>E. S. A.</given-names></string-name>, <string-name><surname>Brinkwirth</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Strassmaier</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ohtsuki</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Danker</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Vanoye</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Polonchuk</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Fermini</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Pierson</surname>, <given-names>J. B.</given-names></string-name>, and <string-name><surname>Gintant</surname>, <given-names>G.</given-names></string-name> <chapter-title>Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells</chapter-title>. <source>Sci Rep</source>, <volume>10</volume>(<issue>1</issue>):<fpage>5627</fpage>, <month>Mar</month>. <year>2020</year>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-62344-w</pub-id>. Number: 1 Publisher: <publisher-name>Nature Publishing Group</publisher-name>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Krogh-Madsen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Jacobson</surname>, <given-names>A. F.</given-names></string-name>, <string-name><surname>Ortega</surname>, <given-names>F. A.</given-names></string-name>, and <string-name><surname>Christini</surname>, <given-names>D. J.</given-names></string-name> <article-title>Global Optimization of Ventricular Myocyte Model to Multi-Variable Objective Improves Predictions of Drug-Induced Torsades de Pointes</article-title>. <source>Front. Physiol</source>., <volume>8</volume>:<fpage>1059</fpage>, <month>Dec</month>. <year>2017</year>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2017.01059</pub-id>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Lancaster</surname>, <given-names>M. C.</given-names></string-name> and <string-name><surname>Sobie</surname>, <given-names>E.</given-names></string-name> <article-title>Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms</article-title>. <source>Clin. Pharmacol. Ther</source>., <volume>100</volume>(<issue>4</issue>):<fpage>371</fpage>–<lpage>379</lpage>, <year>2016</year>. doi: <pub-id pub-id-type="doi">10.1002/cpt.367</pub-id>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Lancaster</surname>, <given-names>M.</given-names></string-name> and <string-name><surname>Sobie</surname>, <given-names>E.</given-names></string-name> <collab>Response to “Complexity vs</collab>. <article-title>Simplicity: The Winner Is?” Mechanism-Based Classifiers Provide More Than Just Classification</article-title>. <source>Clin. Pharmacol. Ther</source>., <volume>101</volume>(<issue>3</issue>):<fpage>327</fpage>–<lpage>327</lpage>, <month>Mar</month>. <year>2017</year>. doi: <pub-id pub-id-type="doi">10.1002/cpt.500</pub-id>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="book"><string-name><surname>Li</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Dutta</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sheng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tran</surname>, <given-names>P. N.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mdluli</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Strauss</surname>, <given-names>D. G.</given-names></string-name>, and <string-name><surname>Colatsky</surname>, <given-names>T.</given-names></string-name> <chapter-title>Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel–Drug Binding Kinetics and Multichannel Pharmacology</chapter-title>. <source>Circ Arrhythm Electrophysiol</source>, <volume>10</volume>(<issue>2</issue>):<fpage>e004628</fpage>, <month>Feb</month>. <year>2017</year>. doi: <pub-id pub-id-type="doi">10.1161/CIRCEP.116.004628</pub-id>. Publisher: <publisher-name>American Heart Association</publisher-name>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Ridder</surname>, <given-names>B. J.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>W. W.</given-names></string-name>, <string-name><surname>Sheng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tran</surname>, <given-names>P. N.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Randolph</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Johnstone</surname>, <given-names>R. H.</given-names></string-name>, <string-name><surname>Mirams</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Kuryshev</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Kramer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Crumb</surname> <suffix>Jr</suffix>., <given-names>W. J.</given-names></string-name>, and <string-name><surname>Strauss</surname>, <given-names>D. G.</given-names></string-name> <article-title>Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative</article-title>. <source>Clin. Pharmacol. Ther</source>., <volume>105</volume>(<issue>2</issue>):<fpage>466</fpage>–<lpage>475</lpage>, <year>2019</year>. doi: <pub-id pub-id-type="doi">10.1002/cpt.1184</pub-id>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Llopis-Lorente</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gomis-Tena</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cano</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Romero</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Saiz</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Trenor</surname>, <given-names>B.</given-names></string-name> <article-title>In Silico Classifiers for the Assessment of Drug Proarrhythmicity</article-title>. <source>J. Chem. Inf. Model</source>., <volume>60</volume>(<issue>10</issue>): <fpage>5172</fpage>–<lpage>5187</lpage>, <month>Oct</month>. <year>2020</year>. doi: <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00201</pub-id>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Mann</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Imtiaz</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Winbo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Rydberg</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Perry</surname>, <given-names>M. D.</given-names></string-name>, <string-name><surname>Couderc</surname>, <given-names>J.-P.</given-names></string-name>, <string-name><surname>Polonsky</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>McNitt</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zareba</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A. P.</given-names></string-name>, and <string-name><surname>Vandenberg</surname>, <given-names>J. I.</given-names></string-name> <article-title>Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes</article-title>. <source>J Mol Cell Cardiol</source>, <volume>100</volume>:<fpage>25</fpage>–<lpage>34</lpage>, <month>Nov</month>. <year>2016</year>. doi: <pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.09.011</pub-id>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Martin</surname>, <given-names>R. L.</given-names></string-name>, <string-name><surname>McDermott</surname>, <given-names>J. S.</given-names></string-name>, <string-name><surname>Salmen</surname>, <given-names>H. J.</given-names></string-name>, <string-name><surname>Palmatier</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cox</surname>, <given-names>B. F.</given-names></string-name>, and <string-name><surname>Gintant</surname>, <given-names>G. A.</given-names></string-name> <article-title>The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block</article-title>. <source>J Cardiovasc Pharmacol</source>, <volume>43</volume>(<issue>3</issue>):<fpage>369</fpage>, <month>Mar</month>. <year>2004</year>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Mirams</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Cui</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Sher</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Fink</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cooper</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Heath</surname>, <given-names>B. M.</given-names></string-name>, <string-name><surname>McMahon</surname>, <given-names>N. C.</given-names></string-name>, <string-name><surname>Gavaghan</surname>, <given-names>D. J.</given-names></string-name>, and <string-name><surname>Noble</surname>, <given-names>D.</given-names></string-name> <article-title>Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk</article-title>. <source>Cardiovascular Research</source>, <volume>91</volume> (<issue>1</issue>):<fpage>53</fpage>–<lpage>61</lpage>, <month>July</month> <year>2011</year>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvr044</pub-id>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Mistry</surname>, <given-names>H. B.</given-names></string-name>, <string-name><surname>Davies</surname>, <given-names>M. R.</given-names></string-name>, and <string-name><surname>Di Veroli</surname>, <given-names>G. Y.</given-names></string-name> <article-title>A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment</article-title>. <source>Front Pharmacol</source>, <volume>6</volume>, <year>2015</year>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Mistry</surname>, <given-names>H. B. Complexity vs</given-names></string-name>. <article-title>Simplicity: The Winner Is?</article-title> <source>Clin. Pharmacol. Ther</source>., <volume>101</volume>(<issue>3</issue>): <fpage>326</fpage>–<lpage>326</lpage>, <month>Mar</month>. <year>2017</year>. doi: <pub-id pub-id-type="doi">10.1002/cpt.503</pub-id>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Mistry</surname>, <given-names>H. B.</given-names></string-name> <article-title>Complex versus simple models: ion-channel cardiac toxicity prediction</article-title>. <source>PeerJ</source>, <volume>6</volume>:<fpage>e4352</fpage>, <month>Feb</month>. <year>2018</year>. doi: <pub-id pub-id-type="doi">10.7717/peerj.4352</pub-id>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Mistry</surname>, <given-names>H. B.</given-names></string-name> <article-title>Comprehensive In Vitro Proarrhythmic Assay Complexity Bias</article-title>. <source>Clin. Pharmacol. Ther</source>., <volume>105</volume>(<issue>6</issue>):<fpage>1323</fpage>–<lpage>1324</lpage>, <month>June</month> <year>2019</year>. doi: <pub-id pub-id-type="doi">10.1002/cpt.1400</pub-id>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Morotti</surname>, <given-names>S.</given-names></string-name> and <string-name><surname>Grandi</surname>, <given-names>E.</given-names></string-name> <article-title>Logistic regression analysis of populations of electrophysiological models to assess proarrythmic risk</article-title>. <source>MethodsX</source>, <volume>4</volume>:<fpage>25</fpage>–<lpage>34</lpage>, <month>Jan</month>. <year>2017</year>. doi: <pub-id pub-id-type="doi">10.1016/j.mex.2016.12.002</pub-id>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="book"><string-name><surname>Ni</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Morotti</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Grandi</surname>, <given-names>E. A</given-names></string-name> <chapter-title>heart for diversity: simulating variability in cardiac arrhythmia research</chapter-title>. <source>Front Physiol</source>, <volume>9</volume>:<fpage>958</fpage>, <year>2018</year>. Publisher: <publisher-name>Frontiers</publisher-name>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>O’Hara</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Virág</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Varró</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Rudy</surname>, <given-names>Y.</given-names></string-name> <article-title>Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation</article-title>. <source>PLoS Comput Biol</source>, <volume>7</volume>(<issue>5</issue>):<fpage>e1002061</fpage>, <month>May</month> <year>2011</year>. doi: <pub-id pub-id-type="doi">10.1371/journal.pcbi.1002061</pub-id>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Passini</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Britton</surname>, <given-names>O. J.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>H. R.</given-names></string-name>, <string-name><surname>Rohrbacher</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hermans</surname>, <given-names>A. N.</given-names></string-name>, <string-name><surname>Gallacher</surname>, <given-names>D. J.</given-names></string-name>, <string-name><surname>Greig</surname>, <given-names>R. J. H.</given-names></string-name>, <string-name><surname>Bueno-Orovio</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Rodriguez</surname>, <given-names>B.</given-names></string-name> <article-title>Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity</article-title>. <source>Front Physiol</source>, <volume>8</volume>:<fpage>668</fpage>, <year>2017</year>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2017.00668</pub-id>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Pugsley</surname>, <given-names>M. K.</given-names></string-name>, <string-name><surname>Authier</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Curtis</surname>, <given-names>M. J.</given-names></string-name> <article-title>Principles of Safety Pharmacology</article-title>. <source>Br J Phar-macol</source>, <volume>154</volume>(<issue>7</issue>):<fpage>1382</fpage>–<lpage>1399</lpage>, <year>2008</year>. doi: <pub-id pub-id-type="doi">10.1038/bjp.2008.280</pub-id>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Sadrieh</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mann</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Subbiah</surname>, <given-names>R. N.</given-names></string-name>, <string-name><surname>Domanski</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Taylor</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Vandenberg</surname>, <given-names>J. I.</given-names></string-name>, and <string-name><surname>Hill</surname>, <given-names>A. P.</given-names></string-name> <article-title>Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram: Sensitivity analysis of ECG signals</article-title>. <source>J Physiol</source>, <volume>591</volume>(<issue>17</issue>):<fpage>4207</fpage>–<lpage>4222</lpage>, <month>Sept</month>. <year>2013</year>. doi: <pub-id pub-id-type="doi">10.1113/jphysiol.2013.251710</pub-id>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Sadrieh</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Domanski</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Pitt-Francis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mann</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Hodkinson</surname>, <given-names>E. C.</given-names></string-name>, <string-name><surname>Ng</surname>, <given-names>C.-A.</given-names></string-name>, <string-name><surname>Perry</surname>, <given-names>M. D.</given-names></string-name>, <string-name><surname>Taylor</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Gavaghan</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Subbiah</surname>, <given-names>R. N.</given-names></string-name>, <string-name><surname>Vandenberg</surname>, <given-names>J. I.</given-names></string-name>, and <string-name><surname>Hill</surname>, <given-names>A. P.</given-names></string-name> <article-title>Multiscale cardiac modelling reveals the origins of notched T waves in long QT syndrome type 2</article-title>. <source>Nat Commun</source>, <volume>5</volume>(<issue>1</issue>), <month>Dec</month>. <year>2014</year>. doi: <pub-id pub-id-type="doi">10.1038/ncomms6069</pub-id>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="book"><string-name><surname>Sobie</surname>, <given-names>E. A.</given-names></string-name> <chapter-title>Parameter sensitivity analysis in electrophysiological models using multivariable regression</chapter-title>. <source>Biophys J</source>, <volume>96</volume>(<issue>4</issue>):<fpage>1264</fpage>–<lpage>1274</lpage>, <year>2009</year>. Publisher: <publisher-name>Elsevier</publisher-name>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>TeBay</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>McArthur</surname>, <given-names>J. R.</given-names></string-name>, <string-name><surname>Mangala</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kerr</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Heitmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Perry</surname>, <given-names>M. D.</given-names></string-name>, <string-name><surname>Windley</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>Vandenberg</surname>, <given-names>J. I.</given-names></string-name>, and <string-name><surname>Hill</surname>, <given-names>A. P.</given-names></string-name> <article-title>Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation</article-title>. <source>Br J Pharmacol</source>, <volume>179</volume>(<issue>11</issue>):<fpage>2631</fpage>–<lpage>2646</lpage>, <month>June</month> <year>2022</year>. doi: <pub-id pub-id-type="doi">10.1111/bph.15757</pub-id>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Varshneya</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mei</surname>, <given-names>X.</given-names></string-name>, and <string-name><surname>Sobie</surname>, <given-names>E. A.</given-names></string-name> <article-title>Prediction of arrhythmia susceptibility through mathematical modeling and machine learning</article-title>. <source>PNAS</source>, <volume>118</volume>(<issue>37</issue>):<fpage>e2104019118</fpage>, <month>Sept</month>. <year>2021</year>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2104019118</pub-id>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Witchel</surname>, <given-names>H. J.</given-names></string-name> <article-title>Drug-induced hERG Block and Long QT Syndrome</article-title>. <source>Cardiovasc Ther</source>, <volume>29</volume>(<issue>4</issue>): <fpage>251</fpage>–<lpage>259</lpage>, <year>2011</year>. doi: <pub-id pub-id-type="doi">10.1111/j.1755-5922.2010.00154.x</pub-id>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="web"><string-name><surname>Woosley</surname>, <given-names>R. L.</given-names></string-name>, <string-name><surname>Heise</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gallo</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Woosley</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Romero</surname>, <given-names>K. A.</given-names></string-name> <source>Risk categories for drugs that prolong QT and induce Torsade de Pointes (TdP)</source>, <year>2019</year>. URL <ext-link ext-link-type="uri" xlink:href="https://www.crediblemeds.org/">https://www.crediblemeds.org/</ext-link>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="book"><string-name><surname>Yap</surname>, <given-names>Y. G.</given-names></string-name> and <string-name><surname>Camm</surname>, <given-names>A. J.</given-names></string-name> <chapter-title>Drug induced QT prolongation and torsades de pointes</chapter-title>. <source>Heart</source>, <volume>89</volume>(<issue>11</issue>):<fpage>1363</fpage>–<lpage>1372</lpage>, <month>Nov</month>. <year>2003</year>. doi: <pub-id pub-id-type="doi">10.1136/heart.89.11.1363</pub-id>. Publisher: <publisher-name>BMJ Publishing Group Ltd Section: Education in Heart</publisher-name>.</mixed-citation></ref>
</ref-list>
<sec id="s6">
<title>Supplementary Videos</title>
<fig id="figS1" position="float" fig-type="figure">
<label>Supplementary Video SV1</label>
<caption><p>Animation of <xref rid="fig4" ref-type="fig">Figure 4</xref> illustrating the relationship between drug risk and population risk. <bold>A</bold>. Drug-induced shift of the the natural population along the axis of arrhythmia. The size of the shift corresponds to the risk score of the drug. <bold>B</bold>. The <italic>a priori</italic> probability of ectopy along the axis of arrhythmia (shaded) in conjunction with the natural population density (light gray). <bold>C</bold>. The probability of ectopy for the natural population (black line) against the <italic>a priori</italic> probability of ectopy (shaded).</p></caption>
<graphic xlink:href="537441v3_figSV1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s7">
<title>Supplementary Information</title>
<table-wrap id="tblS1" orientation="portrait" position="float">
<label>Supplementary Dataset S1</label>
<caption><p>The drug response data in CSV format. The data was reconstructed from the <italic>IC</italic><sub>50</sub> values published in Supplementary Table S2 of <xref ref-type="bibr" rid="c21">Llopis-Lorente et al (2020)</xref>. The Hill coefficient was assumed to be <italic>h</italic> = 1 in all cases. Ion channels with missing values were assumed to be unaffected by the drug (<italic>δ</italic> = 1). The clinical risk labels were transcribed from <xref rid="tbl1" ref-type="table">Table 1</xref> of <xref ref-type="bibr" rid="c21">Llopis-Lorente et al (2020)</xref></p></caption>
<graphic xlink:href="537441v3_tblS1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<sec id="s7a">
<title>Drugs with Class 1 Torsadogenic risk</title>
<fig id="ufig1" position="float" fig-type="figure">
<graphic xlink:href="537441v3_ufig1.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig1a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig1b.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig1c.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig1d.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig1e.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig1f.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s7b">
<title>Drugs with Class 2 Torsadogenic risk</title>
<fig id="ufig2" position="float" fig-type="figure">
<graphic xlink:href="537441v3_ufig2.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig2a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig2b.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s7c">
<title>Drugs with Class 3 Torsadogenic risk</title>
<fig id="ufig3" position="float" fig-type="figure">
<graphic xlink:href="537441v3_ufig3.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig3a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig3b.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s7d">
<title>Drugs with Class 4 Torsadogenic risk</title>
<fig id="ufig4" position="float" fig-type="figure">
<graphic xlink:href="537441v3_ufig4.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4b.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4c.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4d.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4e.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4f.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="537441v3_ufig4g.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.90027.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Christopher L-H</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>University of Cambridge</institution>
</institution-wrap>
<city>Cambridge</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>compelling</bold> and novel mathematical method assesses drug pro-arrhythmic cardiotoxicity by examining the electrophysiology of untreated cardiac cells. It will be <bold>valuable</bold> for future drug safety design.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.90027.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
Heitmann et al introduce a novel method for predicting the potential of drug candidates to cause Torsades de Pointes using simulations. Despite the fact that a multitude of such methods have been proposed in the past decade, this approach manages to provide novelty in a way that is potentially paradigm-shifting. The figures are beautiful and manage to convey difficult concepts intuitively.</p>
<p>Strengths:</p>
<p>
(1) Novel combination of detailed mechanistic simulations with rigorous statistical modeling</p>
<p>(2) A method for predicting drug safety that can be used during drug development</p>
<p>(3) A clear explication of difficult concepts.</p>
<p>Weaknesses:</p>
<p>
(1) In this reviewer's opinion, the most important scientific issue that can be addressed is the fact that when a drug blocks multiple channels, it is not only the IC50 but also the Hill coefficient that can differ. By the same token, two drugs that block the same channel may have identical IC50s but different Hill coefficients. This is important to consider since concentration-dependence is an important part of the results presented here. If the Hill coefficients were to be significantly different, the concentration-dependent curves shown in Figure 6 could look very different.</p>
<p>(2) The curved lines shown in Figure 6 can initially be difficult to comprehend, especially when all the previous presentations emphasized linearity. But a further issue is obscured in these plots, which is the fact that they show a two-dimensional projection of a 4-dimensional space. Some of the drugs might hit the channels that are not shown (INaL &amp; IKs), whereas others will not. It is unclear, and unaddressed in the manuscript, how differences in the &quot;hidden channels&quot; will influence the shapes of these curves. An example, or at least some verbal description, could be very helpful.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.90027.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
In the paper from Hartman, Vandenberg, and Hill entitled &quot;assessing drug safety, by identifying the access of arrhythmia and cardio, myocytes, electro physiology&quot;, the authors, define a new metric, the axis of arrhythmia&quot; that essentially describes the parameter space of ion channel conductance combinations, where early after depolarization can be observed.</p>
<p>Strengths:</p>
<p>
There is an elegance to the way the authors have communicated the scoring system. The method is potentially useful because of its simplicity, accessibility, and ease of use. I do think it adds to the field for this reason - a number of existing methods are overly complex and unwieldy and not necessarily better than the simple parameter regime scan presented here.</p>
<p>Weaknesses:</p>
<p>
The method described in the manuscript suffers from a number of weaknesses that plague current screening methods. Included in these are the data quality and selection used to inform the drug-blocking profile. It's well known that drug measurements vary widely, depending on the measurement conditions.</p>
<p>There doesn't seem to be any consideration of pacing frequency, which is an important consideration for arrhythmia triggers, resulting from repolarization abnormalities, but also depolarization abnormalities. Extremely high doses of drugs are used to assess the population risk. But does the method yield important information when realistic drug concentrations are used? In the discussion, the comparison to conventional approaches suggests that the presented method isn't necessarily better than conventional methods.</p>
<p>In conclusion, I have struggled to grasp the exceptional novelty of the new metric as presented, especially when considering that the badly needed future state must include a component of precision medicine.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.90027.1.sa3</article-id>
<title-group>
<article-title>Author Response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Heitmann</surname>
<given-names>Stewart</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3351-9514</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Vandenberg</surname>
<given-names>Jamie I</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3859-3716</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Hill</surname>
<given-names>Adam P</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6403-1282</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>We thank the reviewers for their thoughtful suggestions, which we will address in the revised manuscript.</p>
<p>Briefly, we purposely fixed the Hill coefficients to h=1 on the grounds that one drug molecule binding to the channel is sufficient to block the channel and there is no strong evidence for co-operative binding in the literature. Doing so also helped to constrain the degrees of freedom in the face of noisy observations in the public datasets. As noted by Reviewer 2, the quality of the drug measurements varies widely across laboratories and this is particularly noticeable in estimates of Hill coefficients which are therefore less reliable.</p>
<p>The dose-dependent curves of multi-channel block (Figure 6) are plotted for all four dimensions in the Supplementary Dataset. We omitted GKs and GNaL from Figure 6 in an attempt at brevity since they do not add much to the story.</p>
<p>It is true that pacing frequency was not considered in this study.</p>
<p>The drugs were assessed across a range of doses (1x to 30x) but dosage only had a minimal impact on accuracy (88.1% to 90.8%) as shown in Figure 8A.</p>
<p>Finally, we emphasize that the metric’s novelty lies in deriving a simple linear model from biophysical principles of ion-channel blockade rather than blind statistical model fitting.</p>
</body>
</sub-article>
</article>